Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

Interestingly, CD4 + T lymphocytes with low expression of CD27 and CD28, indicative of effector memory T cells, showed a trend toward a higher concentration in responders at baseline and increased throughout treatment, reaching statistical significance at follow-up ( P = 0.04; Supplementary Fig.

also in 23,610 other papers

In contrast, we observed higher expression of markers related to T cell–mediated response (CD4 and CD8) in the diagnostic samples, with these changes being significant for CD4 ( P = 0.006) and showing a statistical trend for CD8 ( P value = 0.08; Fig. 1A ; Supplementary File S1).

also in 942 other papers